AstraZeneca (AZN) PT Set at GBX 4,550 by UBS

AstraZeneca (LON:AZN) has been assigned a GBX 4,550 ($61.72) target price by equities research analysts at UBS in a report released on Friday, www.boersen-zeitung.de reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS’s price target would indicate a potential downside of 12.97% from the stock’s current price.

A number of other brokerages have also recently issued reports on AZN. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a report on Wednesday, April 11th. JPMorgan Chase reiterated an “overweight” rating and issued a GBX 5,500 ($74.61) price objective on shares of AstraZeneca in a report on Friday, February 2nd. Jefferies Group set a GBX 5,075 ($68.84) price objective on shares of AstraZeneca and gave the stock a “neutral” rating in a report on Monday, February 26th. Liberum Capital reiterated a “hold” rating and issued a GBX 5,000 ($67.82) price objective on shares of AstraZeneca in a report on Friday, January 26th. Finally, BNP Paribas reiterated an “outperform” rating and issued a GBX 5,600 ($75.96) price objective on shares of AstraZeneca in a report on Thursday, March 22nd. Four analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of GBX 5,255.78 ($71.29).

Shares of LON:AZN opened at GBX 5,228 ($70.92) on Friday. AstraZeneca has a 1 year low of GBX 4,260 ($57.79) and a 1 year high of GBX 5,520 ($74.88).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Acquires Shares of 30,300 LSC Communications
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
Mackay Shields LLC Invests $553,000 in Range Resources Corp.
50,700 Shares in Immersion Co.  Purchased by Mackay Shields LLC
50,700 Shares in Immersion Co. Purchased by Mackay Shields LLC
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
SG Americas Securities LLC Takes $952,000 Position in Core-Mark Holding Company, Inc.
Schlumberger Limited.  Position Boosted by Zeke Capital Advisors LLC
Schlumberger Limited. Position Boosted by Zeke Capital Advisors LLC
Aecon Group’s  “Outperform Overweight” Rating Reiterated at National Bank Financial
Aecon Group’s “Outperform Overweight” Rating Reiterated at National Bank Financial


Leave a Reply

 
© 2006-2018 Zolmax.